|
|
Article: Regeneron Completes Rolling BLA For IL-1 Trap In CAPS.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Hoping to introduce the first marketed product for a group of rare chronic inflammatory conditions, Regeneron Pharmaceuticals Inc. completed a rolling biologics license application for its interleukin-1 (IL-1) Trap.
That BLA is the first to emerge from the company's Trap program, which also includes two partnered VEGF Trap candidates targeting cancer and wet age-related macular degeneration.
Assuming the product gets a priority review by the FDA, as requested, the IL-1 Trap could gain approval within six months for cryopyrin-associated periodic syndrome (CAPS).
The agency previously granted fast-track and orphan drug ...